IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-armed, open label study on the efficacy and safety of
sequential IP therapy(Irinotecan plus cisplatin) and octreotide lar in the treatment of GI
poorly diffrentiated Neuroendocrine carcinoma. Patient with written consents will enter the
phase one step of the trial, receiving IP therpy. Once the IP therapy has been finished
without disease progression or progression occurs during the treatment, the patient will
enter the phase two step of the trial, receiving octreotide treatment. The primary endpoint
is progression free survival in the two steps respectively and secondary endpoint is disease
control rate, overall survival and safety